COX2 expression is associated with proliferation and tumor extension in vestibular schwannoma but is not influenced by acetylsalicylic acid intake

Table 2 Univariate analysis of COX2 expression (ID-Score)

	n (%)	Mean (95%CI)	p-value (ANOVA)
Age (years)
< 56.19	777 (74)	1.83 (1.78–1.89)	< 0.0001*
> =56.19	271 (26)	2.07 (1.99–2.16)
MIB1 (% expression)
< 1.03	319 (30)	1.68 (1.60–1.76)	< 0.0001*
> =1.03	729 (70)	1.99 (1.94–2.04)
Gender
Female	544 (52)	1.95 (1.89–2.01)	0.0179*
Male	504 (48)	1.84 (1.78–1.90)
Primary/Recurrence
Primary	992 (95)	1.89 (1.84–1.94)	0.7074
Recurrence	56 (5)	1.93 (1.74–2.13)
Subtype
Sporadic VS	933 (89)	1.92 (1.88–1.97)	0.0005*
NF2 VS	115 (11)	1.67 (1.54–1.81)
Prior Treatment
None	1011 (96)	1.88 (1.84–1.93)	0.0009*
Radiotherapy	37 (4)	2.29 (2.05–2.53)
Hannover Classification
T1	49 (5)	1.17 (0.98–1.37)	< 0.0001*
T2	220 (21)	1.62 (1.53–1.71)
T3	402 (38)	1.92 (1.85–1.99)
T4	377 (36)	2.12 (2.05–2.20)
T1/2	269 (26)	1.54 (1.45–1.62)	< 0.0001*
T3/4	779 (74)	2.02 (1.97–2.07)
Medication
ASA	49 (5)	2.03 (1.82–2.23)	0.2046
No ASA	999 (95)	1.89 (1.84–1.94)
NSAID	77 (7)	1.93 (1.76–2.09)	0.6887
No NSAID	971 (93)	1.89 (1.85–1.94)
COX2-Inhibitor	2 (0.2)	2.25 (1.23–3.27)	0.4967
No COX-Inhibitor	1046 (99)	1.90 (1.85–1.94)
Cortisol	27 (3)	2.02 (1.74–2.30)	0.3821
No Cortisol	1021 (97)	1.89 (1.85–1.94)
Immunosuppressants (incl. cortisol)	32 (3)	2.00 (1.74–2.26)	0.4183
No immunosuppressants	1016 (97)	1.89 (1.85–1.94)

ISSN: 2051-5960